Romania

Romania

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
0.97 (0.83 - 1.11) 2019 Modelled IHME
0.97 (0.85 - 1.10) 2018 Modelled IHME
0.97 (0.85 - 1.11) 2017 Modelled IHME
0.97 (0.85 - 1.10) 2016 Modelled IHME
0.98 (0.84 - 1.11) 2015 Modelled IHME
0.98 (0.85 - 1.11) 2014 Modelled IHME
1 (0.87 - 1.13) 2013 Modelled IHME
1.02 (0.89 - 1.16) 2012 Modelled IHME
1.05 (0.91 - 1.19) 2011 Modelled IHME
1.07 (0.92 - 1.22) 2010 Modelled IHME
1.09 (0.94 - 1.24) 2009 Modelled IHME
1.11 (0.96 - 1.26) 2008 Modelled IHME
1.13 (0.97 - 1.28) 2007 Modelled IHME
1.15 (0.99 - 1.31) 2006 Modelled IHME
1.17 (1 - 1.34) 2005 Modelled IHME
1.19 (1.02 - 1.36) 2004 Modelled IHME
1.21 (1.04 - 1.38) 2003 Modelled IHME
1.23 (1.06 - 1.39) 2002 Modelled IHME
1.25 (1.08 - 1.43) 2001 Modelled IHME
1.27 (1.10 - 1.46) 2000 Modelled IHME
1.29 (1.12 - 1.47) 1999 Modelled IHME
1.31 (1.14 - 1.48) 1998 Modelled IHME
1.33 (1.15 - 1.50) 1997 Modelled IHME
1.35 (1.17 - 1.53) 1996 Modelled IHME
1.37 (1.18 - 1.55) 1995 Modelled IHME
1.38 (1.19 - 1.56) 1994 Modelled IHME
1.39 (1.20 - 1.56) 1993 Modelled IHME
1.4 (1.21 - 1.58) 1992 Modelled IHME
1.4 (1.22 - 1.59) 1991 Modelled IHME
1.41 (1.22 - 1.59) 1990 Modelled IHME
5.59 2010 Survey/reported Voiculescu M et al, 2010
4.4 (4 - 4.80) 2013 Survey/reported Gheorghe L et al, 2013
4.79 (3.95 - 5.84) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.14 (0.10 - 0.18) 2019 Modelled IHME
0.14 (0.11 - 0.18) 2018 Modelled IHME
0.14 (0.11 - 0.19) 2017 Modelled IHME
0.13 (0.10 - 0.17) 2016 Modelled IHME
0.12 (0.09 - 0.16) 2015 Modelled IHME
0.12 (0.09 - 0.15) 2014 Modelled IHME
0.11 (0.08 - 0.14) 2013 Modelled IHME
0.1 (0.08 - 0.13) 2012 Modelled IHME
0.1 (0.07 - 0.12) 2011 Modelled IHME
0.09 (0.07 - 0.12) 2010 Modelled IHME
0.08 (0.06 - 0.10) 2009 Modelled IHME
0.07 (0.05 - 0.09) 2008 Modelled IHME
0.06 (0.05 - 0.08) 2007 Modelled IHME
0.06 (0.04 - 0.07) 2006 Modelled IHME
0.05 (0.04 - 0.07) 2005 Modelled IHME
0.05 (0.04 - 0.07) 2004 Modelled IHME
0.05 (0.04 - 0.07) 2003 Modelled IHME
0.05 (0.04 - 0.06) 2002 Modelled IHME
0.05 (0.04 - 0.06) 2001 Modelled IHME
0.05 (0.04 - 0.07) 2000 Modelled IHME
0.05 (0.04 - 0.07) 1999 Modelled IHME
0.05 (0.04 - 0.07) 1998 Modelled IHME
0.06 (0.04 - 0.07) 1997 Modelled IHME
0.06 (0.05 - 0.08) 1996 Modelled IHME
0.07 (0.05 - 0.09) 1995 Modelled IHME
0.12 (0.09 - 0.15) 1994 Modelled IHME
0.24 (0.18 - 0.31) 1993 Modelled IHME
0.42 (0.32 - 0.55) 1992 Modelled IHME
0.64 (0.49 - 0.83) 1991 Modelled IHME
0.88 (0.66 - 1.16) 1990 Modelled IHME
0.65 (0.44 - 0.93) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
19 (13 - 26) 2019 Modelled IHME
19 (13 - 26) 2018 Modelled IHME
19 (13 - 26) 2017 Modelled IHME
19 (14 - 26) 2016 Modelled IHME
19 (14 - 27) 2015 Modelled IHME
19 (14 - 27) 2014 Modelled IHME
19 (14 - 27) 2013 Modelled IHME
19 (14 - 27) 2012 Modelled IHME
19 (14 - 27) 2011 Modelled IHME
20 (14 - 27) 2010 Modelled IHME
20 (14 - 27) 2009 Modelled IHME
20 (14 - 27) 2008 Modelled IHME
20 (14 - 27) 2007 Modelled IHME
20 (14 - 27) 2006 Modelled IHME
20 (14 - 27) 2005 Modelled IHME
20 (14 - 27) 2004 Modelled IHME
21 (15 - 28) 2003 Modelled IHME
21 (15 - 29) 2002 Modelled IHME
22 (16 - 30) 2001 Modelled IHME
23 (16 - 31) 2000 Modelled IHME
23 (16 - 31) 1999 Modelled IHME
23 (16 - 31) 1998 Modelled IHME
23 (17 - 32) 1997 Modelled IHME
23 (17 - 32) 1996 Modelled IHME
24 (17 - 32) 1995 Modelled IHME
24 (17 - 32) 1994 Modelled IHME
24 (17 - 32) 1993 Modelled IHME
24 (17 - 32) 1992 Modelled IHME
23 (17 - 32) 1991 Modelled IHME
24 (17 - 32) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
36 2018 Survey/reported WHO/UNICEF
36 2017 Survey/reported WHO/UNICEF
93 2016 Survey/reported WHO/UNICEF
96 2015 Survey/reported WHO/UNICEF
73 2014 Survey/reported WHO/UNICEF
98 2013 Survey/reported WHO/UNICEF
99 2012 Survey/reported WHO/UNICEF
99 2011 Survey/reported WHO/UNICEF
98 2010 Survey/reported WHO/UNICEF
97 2009 Survey/reported WHO/UNICEF
99 2008 Survey/reported WHO/UNICEF
90 2007 Survey/reported WHO/UNICEF
99 2006 Survey/reported WHO/UNICEF
99 2005 Survey/reported WHO/UNICEF
99 2004 Survey/reported WHO/UNICEF
99 2003 Survey/reported WHO/UNICEF
99 2002 Survey/reported WHO/UNICEF
99 2001 Survey/reported WHO/UNICEF
99 2000 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
93 2018 Survey/reported WHO/UNICEF
92 2017 Survey/reported WHO/UNICEF
90 2016 Survey/reported WHO/UNICEF
90 2015 Survey/reported WHO/UNICEF
94 2014 Survey/reported WHO/UNICEF
96 2013 Survey/reported WHO/UNICEF
96 2012 Survey/reported WHO/UNICEF
96 2011 Survey/reported WHO/UNICEF
98 2010 Survey/reported WHO/UNICEF
95 2009 Survey/reported WHO/UNICEF
97 2008 Survey/reported WHO/UNICEF
99 2007 Survey/reported WHO/UNICEF
99 2006 Survey/reported WHO/UNICEF
98 2005 Survey/reported WHO/UNICEF
99 2004 Survey/reported WHO/UNICEF
98 2003 Survey/reported WHO/UNICEF
99 2002 Survey/reported WHO/UNICEF
98 2001 Survey/reported WHO/UNICEF
98 2000 Survey/reported WHO/UNICEF
99 1999 Survey/reported WHO/UNICEF
99 1998 Survey/reported WHO/UNICEF
99 1997 Survey/reported WHO/UNICEF
99 1996 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
18 (13 - 24) 2014 Survey/reported Romanian Monitoring Centre for Drugs and Drugs Addiction, 2014
Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
8 2017 Survey/reported EMCDDA, 2019
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
1998
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Few (1-10%)
% of substance use disorder facilities offering hepatitis treatment
Few (1-10%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
1.66 (1.35 - 2.03) 2019 Modelled IHME
1.66 (1.35 - 2.06) 2018 Modelled IHME
1.66 (1.35 - 2.07) 2017 Modelled IHME
1.67 (1.35 - 2.05) 2016 Modelled IHME
1.67 (1.36 - 2.07) 2015 Modelled IHME
1.7 (1.38 - 2.07) 2014 Modelled IHME
1.74 (1.44 - 2.08) 2013 Modelled IHME
1.78 (1.50 - 2.10) 2012 Modelled IHME
1.82 (1.56 - 2.13) 2011 Modelled IHME
1.84 (1.58 - 2.15) 2010 Modelled IHME
1.85 (1.58 - 2.17) 2009 Modelled IHME
1.86 (1.58 - 2.18) 2008 Modelled IHME
1.86 (1.58 - 2.18) 2007 Modelled IHME
1.87 (1.58 - 2.19) 2006 Modelled IHME
1.87 (1.59 - 2.20) 2005 Modelled IHME
1.86 (1.57 - 2.18) 2004 Modelled IHME
1.84 (1.54 - 2.17) 2003 Modelled IHME
1.81 (1.50 - 2.16) 2002 Modelled IHME
1.78 (1.45 - 2.17) 2001 Modelled IHME
1.77 (1.42 - 2.19) 2000 Modelled IHME
1.77 (1.42 - 2.18) 1999 Modelled IHME
1.76 (1.43 - 2.17) 1998 Modelled IHME
1.76 (1.43 - 2.17) 1997 Modelled IHME
1.76 (1.42 - 2.16) 1996 Modelled IHME
1.76 (1.42 - 2.17) 1995 Modelled IHME
1.76 (1.42 - 2.15) 1994 Modelled IHME
1.76 (1.41 - 2.15) 1993 Modelled IHME
1.76 (1.41 - 2.15) 1992 Modelled IHME
1.76 (1.41 - 2.16) 1991 Modelled IHME
1.76 (1.41 - 2.16) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
3.2 (2.90 - 3.60) 2008 Survey/reported Gheorghe L et al, 2010
3.2 (2.90 - 3.60) 2014 Modelled Gower et al, 2014
Showing out of
Show more
People who inject drugs (PWID)
Download
Value (%) Year Type Source
83.8 (80.60 - 87.10) 2009 Modelled Degenhardt L et al, 2017

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
26 (18 - 34) 2019 Modelled IHME
26 (18 - 33) 2018 Modelled IHME
26 (18 - 34) 2017 Modelled IHME
26 (18 - 34) 2016 Modelled IHME
25 (18 - 34) 2015 Modelled IHME
25 (18 - 34) 2014 Modelled IHME
25 (18 - 33) 2013 Modelled IHME
25 (18 - 33) 2012 Modelled IHME
25 (18 - 33) 2011 Modelled IHME
25 (18 - 33) 2010 Modelled IHME
25 (17 - 33) 2009 Modelled IHME
25 (17 - 33) 2008 Modelled IHME
25 (18 - 34) 2007 Modelled IHME
25 (18 - 34) 2006 Modelled IHME
25 (18 - 34) 2005 Modelled IHME
25 (18 - 34) 2004 Modelled IHME
25 (18 - 34) 2003 Modelled IHME
25 (18 - 33) 2002 Modelled IHME
25 (18 - 34) 2001 Modelled IHME
25 (18 - 34) 2000 Modelled IHME
25 (18 - 34) 1999 Modelled IHME
25 (17 - 34) 1998 Modelled IHME
25 (17 - 33) 1997 Modelled IHME
25 (17 - 33) 1996 Modelled IHME
25 (17 - 34) 1995 Modelled IHME
25 (18 - 33) 1994 Modelled IHME
25 (18 - 33) 1993 Modelled IHME
25 (18 - 33) 1992 Modelled IHME
25 (18 - 33) 1991 Modelled IHME
25 (18 - 33) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (13 - 24) 2014 Survey/reported Romanian Monitoring Centre for Drugs and Drugs Addiction, 2014
Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
8 2017 Survey/reported EMCDDA, 2019
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
1998
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Few (1-10%)
% of substance use disorder facilities offering hepatitis treatment
Few (1-10%)

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
0.97 (%)
2019
(0.83 - 1.11(%))
IHME
HCV (RNA/cAg+)
1.66 (%)
2019
(1.35 - 2.03(%))
IHME

Survey/surveillance

HBV (HBsAg+)
4.4 (%)
2013
(4 - 4.8(%))
Gheorghe L et al, 2013
HCV (anti-HCV)
3.2 (%)
2008
(2.9 - 3.6(%))
Gheorghe L et al, 2010

Hepatitis related deaths (national)

Modelled

HBV
2,003
2019
(1,397 - 2,806)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
2,186
2019
(1,561 - 3,059)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.14 (%)
2019, latest modelled
(0.10 - 0.18(%))
IHME

Prevalence PWID

HCV
83.80 (%)
2009, latest modelled
(80.60 - 87.10(%))
Degenhardt L et al, 2017

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
36 (%)
2018
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

HCV
18
2014
(13 - 24)
Romanian Monitoring Centre for Drugs and Drugs Addiction, 2014
Eligible for HBV generic medicines
Eligible for HCV generic medicines

Resources